2025 India Adenovirus Vector Vaccine Market Revenue Opportunities Report
Description
The 2025 India Adenovirus Vector Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adenovirus Vector Vaccine Market in India are Serum Institute of India (SII), Bharat Biotech, Cadila Healthcare, and Biological E Ltd. SII, based in Pune, is the world's largest vaccine manufacturer and has been producing the Oxford-AstraZeneca adenovirus-based vaccine, Covishield, at large scale with a production capacity aimed at 2 billion doses per year. Bharat Biotech, Hyderabad, developed Covaxin and is working on an intranasal adenovirus-vectored vaccine BBV154, which is in clinical trials. Cadila Healthcare is developing ZyCoV-D, a DNA plasmid and viral vector vaccine, with large-scale production ongoing and phase 3 trials completed. Biological E has partnered with Johnson & Johnson to manufacture 400 million doses of their adenovirus vector single-shot vaccine approved in the US.
These companies leverage India's strong vaccine manufacturing ecosystem, with over 30 entities capable of producing adenovirus-vectored vaccines such as Oxford-AstraZeneca’s and Gamaleya’s Sputnik V. SII and Biological E have international tie-ups for technology and supply, ramping up capacity to meet domestic and global needs. The Indian adenovirus vector vaccine market is part of the larger viral vector industry projected to grow significantly, reflecting strong demand driven by COVID-19 and broader vaccine development initiatives. This growth is catalyzed by these Indian firms' capacities, partnerships, and clinical trial advancements in adenoviral vector vaccine technology.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adenovirus Vector Vaccine Market in India are Serum Institute of India (SII), Bharat Biotech, Cadila Healthcare, and Biological E Ltd. SII, based in Pune, is the world's largest vaccine manufacturer and has been producing the Oxford-AstraZeneca adenovirus-based vaccine, Covishield, at large scale with a production capacity aimed at 2 billion doses per year. Bharat Biotech, Hyderabad, developed Covaxin and is working on an intranasal adenovirus-vectored vaccine BBV154, which is in clinical trials. Cadila Healthcare is developing ZyCoV-D, a DNA plasmid and viral vector vaccine, with large-scale production ongoing and phase 3 trials completed. Biological E has partnered with Johnson & Johnson to manufacture 400 million doses of their adenovirus vector single-shot vaccine approved in the US.
These companies leverage India's strong vaccine manufacturing ecosystem, with over 30 entities capable of producing adenovirus-vectored vaccines such as Oxford-AstraZeneca’s and Gamaleya’s Sputnik V. SII and Biological E have international tie-ups for technology and supply, ramping up capacity to meet domestic and global needs. The Indian adenovirus vector vaccine market is part of the larger viral vector industry projected to grow significantly, reflecting strong demand driven by COVID-19 and broader vaccine development initiatives. This growth is catalyzed by these Indian firms' capacities, partnerships, and clinical trial advancements in adenoviral vector vaccine technology.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
